A cell-based radioligand binding assay for farnesyl: Protein transferase inhibitors

Journal of Biomolecular Screening

Volumn 8, Issue 4, 2003, Pages 430-438

  Lobell, Robert B ^a   Davide, Joseph P ^a   Kohl, Nancy E ^a   Burns, H Donald ^a   Eng, Wai Si ^a   Gibson, Raymond E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cancer; Cell culture models; CRAFTI; Farnesyltransferase inhibitors; FPTase; P glycoprotein; Radioligand binding assays

Indexed keywords

AMIODARONE; ANTINEOPLASTIC AGENT; CELL PROTEIN; CYCLOSPORIN A; FARNESYL DIPHOSPHATE; IODINE 125; L 778123; MEPACRINE; ONCOPROTEIN; PROTEIN FARNESYLTRANSFERASE; QUINIDINE; RADIOLIGAND; RAS PROTEIN; TRACER; TRANSFERASE INHIBITOR; TRITIUM; VERAPAMIL; VINBLASTINE; ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE; TRANSFERASE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CARBOXY TERMINAL SEQUENCE; CELL ASSAY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVALENT BOND; DOSE RESPONSE; DRUG POTENCY; DRUG TARGETING; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN; HUMAN CELL; IC 50; LIGAND BINDING; NONHUMAN; PRENYLATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; TECHNIQUE; ANIMAL; CELL LINE; CELL STRAIN KB; CHEMISTRY; DRUG ANTAGONISM; DRUG SCREENING; EVALUATION; METABOLISM; METHODOLOGY; RADIOASSAY; SENSITIVITY AND SPECIFICITY;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TRANSFORMED; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS; KB CELLS; RADIOLIGAND ASSAY; RATS; SENSITIVITY AND SPECIFICITY;

EID: 1642468875     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057103256153     Document Type: Article

References (26)

1. Zhang FL, Casey PJ: Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996;65:241-269.
2. Hancock JF, Magee AI, Childs JE, Marshall CJ: All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 1989;57:1167-1177.
3. Jackson JH, Cochrane CG, Bourne JR, Solski PA, Buss JE, Der CJ: Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc Natl Acad Sci USA 1990;87:3042-3046.
4. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ: Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 1992;89:6403-6407.
5. Willumsen BM, Norris K, Papageorge AG, Hubbert NL, Lowy DR: Harvey murine sarcoma virus p21ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus. EMBO J 1984;3:2581-2585.
6. Gibbs JB, Oliff A, Kohl NE: Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 1994;77:175-178.
7. Bell IM: Inhibitors of protein prenylation. Exp Opin Ther Patents 2000;10:1813-1831.
8. Haluska P, Dy GK, Adjei AA: Farnesyl transferase inhibitors as anticancer agents. Eur J Cancer 2002;38:1685-1700.
9. Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, et al: Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res 2001;61:8758-8768.
10. Bell IM, Gallicchio SN, Abrams M, Beshore DC, Buser CA, Culberson JC, et al: Design and biological activity of (S)-4-(5-{[1-(3-chlorobenzyl)-2- oxopyrrolidin-3-ylamino]methyl}imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potency. J Med Chem 2001;44:2933-2949.
11. Beshore DC, Bell IM, Dinsmore CJ, Homnick CF, Culberson JC, Robinson RG, et al: Evaluation of amino acid-based linkers in potent macrocyclic inhibitors of farnesyl-protein transferase. Bioorg Med Chem Lett 2001;11:1817-1821.
12. MacTough SC, DeSolms SJ, Shaw AW, Abrams MT, Ciccarone TR, Davide JP, et al: Diaryl ether inhibitors of farnesyl-protein transferase. Bioorg Med Chem Lett 2001;11:1257-1260.
13. Hamill T, Bums HD, Eng W-S, Francis B, Gibson RE, Fioravanti C: Radioiodinated farnesyltransferase inhibitors. J Labeled Compound Radiopharm 1999;42(Suppl.):S30-S32.
14. Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, et al: Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 1993;260:1934-1937.
15. Williams TM, Bergman JM, Brashear K, Breslin MJ, Dinsmore CJ, Hutchinson JH, et al: N-arylpiperazinone inhibitors of farnesyltransferase: discovery and biological activity. J Med Chem 1999;42:3779-3784.
16. Graham SL, deSolms SJ, Giuliani EA, Kohl NE, Mosser SD, Oliff AI, et al: Pseudopeptide inhibitors of Ras farnesyl-protein transferase. J Med Chem 1994;37:725-732.
17. Shen D-W, Cardarelli C, Hwang J, Corawell M, Richert N, Ishii S, et al: Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem 1986;261:7762-7770.
18. Tiberghien F, Loor F: Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anti-Cancer Drugs 1996;7:568-578.
19. Borst P, Elferink RO: Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537-592.
20. Kanazawa M, Terada K, Kato S, Mori M: HSDJ, a human homolog of DnaJ, is farnesylated and is involved in protein import into mitochondria. J Biochem 1997;121:890-895.
21. Davis AR, Alevy YG, Chellaiah A, Quinn MT, Mohanakumar T: Characterization of HDJ-2, a human 40 kD heat shock protein. Int J Biochem Cell Biol 1998;30:1203-1221.
22. Fukazawa H, Nakano S, Mizuno S, Uehara Y: Inhibitors of anchorage-independent growth affect the growth of transformed cells on Poly(2-hydroxyethylmethacrylate)-coated surfaces. Int J Cancer 1996;67:876-882.
23. Bell IM, Gallicchio SN, Abrams M, Beese LS, Beshore DC, Bhimnathwala H, et al: 3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmaeokinetics and excellent cell potency. J Med Chem 2002:45;2388-2409.
24. Dinsmore CJ, Bergman JM, Wei DD, Zartman CB, Davide JP, Greenberg IB, et al: Oxo-piperazine derivatives of N-arylpiperazinones as inhibitors of farnesyltransferase. Bioorg Med Chem Lett 2001;11:537-540.
25. Nguyen DN, Stump CA, Walsh ES, Fernandes C, Davide JP, Ellis-Hutchings M, et al: Potent inhibitors of farnesyltransferase and geranylgeranyltransferase- 1. Bioorg Med Chem Lett 2002;12:1269-1273.
26. Britten CD, Rowinsky EK, Soignet S, Patnaik A, Yao S-L, Deutsch P, et al: A phase I and pharmacologic study of the farnesyliprotein transferase inhibitor L-778,123 in patients with solid malignancies. Clin Cancer Res 2001;7:3894-3903.